Archive 1995–2023

Neuroleptic treatment increases a risk of body weight gain. It seems the risk is highest during clozapine and olanzapine treatment. Body mass gain is shown in 57-58% of patients treated with olanzapine. Mechanisms of body mass gain, accompanying neuroleptic treatment are not fully understood and require further research.
Authors aimed at review of knowledge about appetite regulation and potential mechanisms of body weight gain with the special regard to olanzapine. Summary of pharmacological methods of prophylaxis and treatment of appetite increase, accompanying neuroleptic treatment is also presented.
Analysis of contemporary knowledge indicates that so for there is no convincing evidence of potential difference in an influence of orally dissolving pills and standard oral tablets forms of olanzapine on body weight gain. In relation to confirmed beneficial effect, correcting the orectic influence of olanzapine, further studies on metformin, topiramate, reboxetine and aripiprazole and perhaps on nizatidine and amantadine are necessary.